Format

Send to

Choose Destination
EMBO Mol Med. 2019 Oct;11(10):e10168. doi: 10.15252/emmm.201810168. Epub 2019 Sep 2.

A circRNA signature predicts postoperative recurrence in stage II/III colon cancer.

Ju HQ1, Zhao Q1, Wang F1,2, Lan P3, Wang Z1,2, Zuo ZX1,4, Wu QN1,5, Fan XJ3, Mo HY1, Chen L4, Li T1, Ren C1, Wan XB3, Chen G1,6, Li YH1,2, Jia WH1, Xu RH1,2.

Author information

1
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
2
Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
3
The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
4
State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen University, Guangzhou, China.
5
Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, China.
6
Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.

Abstract

Accurate risk stratification for patients with stage II/III colon cancer is pivotal for postoperative treatment decisions. Here, we aimed to identify and validate a circRNA-based signature that could improve postoperative prognostic stratification for these patients. In current retrospective analysis, we included 667 patients with R0 resected stage II/III colon cancer. Using RNA-seq analysis of 20 paired frozen tissues collected postoperation, we profiled differential circRNA expression between patients with and without recurrence, followed by quantitative validation. With clinical information, we generated a four-circRNA-based cirScore to classify patients into high-risk and low-risk groups in the training cohort. The patients with high cirScores in the training cohort had a shorter disease-free survival (DFS) and overall survival (OS) than patients with low cirScores. The prognostic capacity of the classifier was validated in the internal and external cohorts. Loss-of-function assays indicated that the selected circRNAs played functional roles in colon cancer progression. Overall, our four-circRNA-based classifier is a reliable prognostic tool for postoperative disease recurrence in patients with stage II/III colon cancer.

KEYWORDS:

biomarker; circular RNA; recurrence; stage II/III colon cancer

PMID:
31475771
DOI:
10.15252/emmm.201810168
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center